zur Navigation zum Inhalt
 
Onkologie 30. Juni 2011

ASH update 2010: Chronic lymphocytic leukaemia

The annual meeting of the American Society of Hematology 2010 offered a wealth of interesting pilot studies in CLL rather than large practice changing trials. Although these new compounds are mostly in a very early phase of drug development, the results are impressive. Concerning clinical practice, new or updated results of trials exploring alemtuzumab in CLL underscore the clinical value of this drug, in particular for high-risk CLL patients. And finally, preliminary data indicate that rituximab maintenance strategies as applied for the treatment of indolent lymphoma may also have a role in CLL.

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben